Immunogenicity and safety of a tetanus-diphtheria vaccine and a 13-valent pneumococcal conjugate vaccine after concomitant vaccination in ≥ 50-year-old adults 11 Medical and Health Sciences 1103 Clinical Sciences

Joon Young Song, Hee Jin Cheong, Ji Yun Noh, Min Joo Choi, Jin Gu Yoon, Saem Na Lee, Seong Hui Kang, Eun Joo Jeong, Yu Mi Jo, Woo Joo Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: When two or more vaccines are administered concurrently, there is concern about safety and immunogenicity from vaccine interaction. Methods: Subjects aged ≥50 years were randomized 1:1:1 to receive tetanus-diphtheria (Td) + 13-valent pneumococcal conjugate vaccine (PCV13; Group 1), PCV13 alone (Group 2), or Td alone (Group 3). After single or concomitant vaccination, enzyme-linked immunosorbent assay and opsonophagocytic assay (OPA) were performed to compare immunogenicity for Td and PCV13, respectively. Results: A total of 448 subjects were available for the assessment. After concomitant administration, the non-inferiority criteria of geometric mean titer (GMT) ratios were met for tetanus, diphtheria, and all four pneumococcal serotypes (1, 5, 18C, and 19A). However, subjects in Group 3 (Td alone) were more likely to have a high IgG anti-tetanus antibody titer (≥ 0.5 U/mL) than those in Group 1 (Td + PCV13) (p < 0.01). As for the pneumococcal serotype 1, the OPA GMT was significantly higher in Group 1 (PCV13 + Td) compared to Group 2 (PCV13 alone) (p = 0.02). No serious adverse event occurred. Conclusions: Concomitant Td and PCV13 administration induced sufficient immunity without significant interference and showed good safety profiles.

Original languageEnglish
Article number628
JournalBMC infectious diseases
Volume18
Issue number1
DOIs
Publication statusPublished - 2018 Dec 5

Keywords

  • Diphtheria
  • Immunogenicity
  • Pneumococcal conjugate vaccine
  • Tetanus

ASJC Scopus subject areas

  • Infectious Diseases

Fingerprint Dive into the research topics of 'Immunogenicity and safety of a tetanus-diphtheria vaccine and a 13-valent pneumococcal conjugate vaccine after concomitant vaccination in ≥ 50-year-old adults 11 Medical and Health Sciences 1103 Clinical Sciences'. Together they form a unique fingerprint.

  • Cite this